Immunotherapy Tecentriq Will Have 'Major Impact' on Bladder Cancer Treatment, WCM Chief Says


Dr. David Nanus

Dr. David Nanus

Dr. David Nanus, the chief of Weill Cornell Medicine's Division of Hematology and Medical Oncology, recently spoke with CURE magazine about the immunotherapy Tecentriq, which received accelerated approval earlier this year from the U.S. Food and Drug Administration for certain patients diagnosed with locally advanced or metastatic urothelial bladder cancer.

Dr. Nanus discussed how Tecentriq and immunotherapy "have already had, and will continue to have, a major impact on the treatment of patients with advanced urothelial bladder cancer," as well as some questions researchers have yet to answer about the medication.

Read Dr. Nanus' full interview here.

In This Article

Clinical Service